Cardiology

Cardiology in 2073

Most of today’s cardiology procedures, technologies, and medications were unknown or in their very early stages fifty years ago, and a new Becker’s Viewpoint by UNC cardiology chief Rick Stouffer, MD forecasts that “cardiology will change as much in the next 50 years.”

Here’s the ten core areas where he expects these changes to take place:

Personalized Medicine – Although very different patients are treated with the same medications today, unique patient characteristics (especially genetics) will play a far greater role in future medication decisions. 

De-Emphasized RTCs – Randomized controlled trials might be the current gold standard for cardiology science, but improvements in EHR data will pave the way for real-time “pragmatic trials” that avoid RCTs’ delays, costs, and hassles.

Environmental Focus – We’ll see a far greater population health-level focus on addressing environmental contributors to CVD (e.g. toxins in water, air pollution, chemicals in food). 

Nutrition Focus – Nutrition will become a major research focus area, noting that nutrition could have a far larger impact on overall CVD health than the CVD drugs that get most of the research attention (and funding).

Cardiomyopathy Progress – There’s currently limited options for heart failure, but the future will bring new therapies that “will recruit myocytes to the failing heart (e.g. stem cell infusions) to replace those irreversibly damaged.”  

Specialist Access – The expansion of telehealth will give patients far more access to subspecialist cardiologists, while general cardiologists will lower their thresholds for subspecialist referrals.

Chronic Interventions We’ll see more chronic diseases treated with interventional procedures, starting with renal denervation for hypertension, and followed by future interventions for “diabetes, heart failure, arrhythmias, etc.”  

Family Ties – We’ll better understand family transmission of cardiovascular disease, as future research into genetic, epigenetic, and environmental factors allow us to identify and treat people with greater inherited risks.

Better and Fewer Procedures – Cardiac procedure and surgery outcomes will continue to improve due to technological and technique advances, but they will “be used less frequently as the focus turns to prevention rather than treatment.”

Preventative Weight Loss – Weight loss will become a primary focus for CVD risk management, with weight loss drugs becoming an early addition to obese patients’ CVD regimens.

What won’t change? 

  • Exercise will still be prescribed but rarely followed 
  • Cheap, non-nutritious foods will continue to be widely available
  • Patients will continue to engage in behaviors that are detrimental to their health 
  • People will still die from heart disease

The Takeaway

Although some of these predictions might be hard to envision (people have far more faith in RTCs than EHR data), they all make a lot of sense. And recent Cardiac Wire issues suggest that some of these trends are already underway.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Pharmaceuticals September 4, 2025

The Differences in HCM, ODYSSEY vs. MAPLE September 4, 2025

In a big step towards better hypertrophic cardiomyopathy treatments, two separate studies presented at ESC suggest cardiac myosin inhibitors’ efficacy depends critically on whether patients have the obstructive or nonobstructive form of the disease. Two similar but different trials presented contrasting outcomes at ESC 2025, with MAPLE-HCM testing aficamten versus metoprolol in obstructive HCM patients, […]

Cardiology August 28, 2025

Cardiologists, Practice What You Preach! August 28, 2025

Cardiologists might be struggling with the same lifestyle challenges they counsel patients about, as a national survey of ACC members revealed significant gaps between what physicians’ recommend and how they act. The ACC CardioSurve study surveyed 166 U.S. cardiologists about their training in lifestyle medicine and clinical recommendations across all six lifestyle pillars, revealing some […]

Obesity Care August 25, 2025

GLP-1s Work, But Not for Free August 25, 2025

Real-world semaglutide (Wegovy) patients might be experiencing a healthcare cost paradox, after a recent analysis in JAMA showed that GLP-1s successfully reduce weight and improve cardiovascular risk factors, but lead to increased patient healthcare expenditures in the short term. The real-world analysis examined 23.5k adults prescribed semaglutide between January 2018 and January 2025 across two […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!